Developmental Research Program

发展研究计划

• 批准号: 10218112
• 负责人: Robert Daniel Beauchamp
• 金额: $ 8.33万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-09 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10218112
• 关键词: Advisory Committees; Area; Cancer Center; Collaborations; Data; Development; Discipline; Emerging Technologies; Extramural Activities; Fostering; Funding; Funding Mechanisms; Future; Goals; Grant; Institution; K-Series Research Career Programs; Lead; Leadership; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Minority; Mission; Neoplasms; Pilot Projects; Procedures; Publications; Research; Research Personnel; Rewards; System; Tennessee; The Vanderbilt-Ingram Cancer Center at the Vanderbilt University; Translational Research; Underrepresented Minority; Underrepresented Populations; United States National Institutes of Health; Universities; Woman; advanced disease; anticancer research; career; design; gastrointestinal; high risk; innovation; medical schools; member; new technology; novel; programs

PROJECT SUMMARY/ABSTRACT: Developmental Research Program The overall objective of the Developmental Research Program (DRP) within the Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal (GI) Cancer (hereafter, VICC GI SPORE) is to encourage innovative translational research in GI neoplasia. The DRP will be led by a Director (R. Daniel Beauchamp, MD) and will be supported by the Developmental Research Advisory Committee (DRAC) made up of senior investigators at Vanderbilt and Meharry Medical College (MMC). The DRP leadership has significant crossover with the Career Enhancement Program (CEP) leadership to encourage CEP recipients to apply for DRP funding and to identify promising investigators from DRP for the CEP. The VICC GI SPORE DRP will use an established and highly effective procedure to solicit applications from investigators at Vanderbilt, MMC, and Tennessee State University. The Director and the DRAC will also actively solicit applications from targeted investigators (women and underrepresented minorities) within the three institutions. Internal and external researchers, including members of the GI SPORE External Advisory Board, will review applications using the NIH 9-point scoring system. Reviewers will evaluate scientific merit and the likelihood of the project to support current GI SPORE activities, lead to extramural funding, and/or lead to future GI SPORE projects. Special emphasis will be placed on attracting young investigators into GI cancer research, high risk/high gain projects, and projects that incorporate emerging technologies and apply them to GI cancer research. Thus, the VICC GI SPORE DRP will offer the opportunity for new directions of study that may be of higher risk but also have a significant chance for reward, including independent funding and additional projects that may form the basis of the next competing renewal.

项目摘要/摘要：发展研究计划 范德比尔特 - 伊格兰癌中发展研究计划（DRP）的总体目标 胃肠道癌（GI）癌症（以下简称VICC GI孢子）的中心孢子是鼓励创新的 胃肠道肿瘤的翻译研究。 DRP将由董事（R. Daniel Beauchamp，马里兰州）领导，威尔 得到由高级调查员的发展研究咨询委员会（DRAC）的支持 范德比尔特和梅哈里医学院（MMC）。 DRP领导与职业生涯有重大的跨界 增强计划（CEP）领导层鼓励CEP接收者申请DRP资金并确定 DRP的有前途的调查员为CEP。 VICC GI孢子DRP将使用已建立且高度的 征求范德比尔特，MMC和田纳西州调查人员申请的有效程序 大学。董事和DRAC还将积极征求目标调查人员的申请（妇女 在三个机构中代表性不足的少数民族。内部和外部研究人员，包括 GI孢子外部顾问委员会的成员将使用NIH 9点评分来审查申请 系统。审稿人将评估科学价值和该项目支持当前的GI孢子的可能性 活动，导致壁外资金和/或导致未来的胃肠道孢子项目。特别重点将放置 吸引年轻的研究人员从事胃肠道癌研究，高风险/高收益项目以及项目 纳入新兴技术并将其应用于胃肠道癌研究。因此，VICC GI孢子DRP将 为新的研究方向提供机会，这可能是较高的风险，但也有很大的机会 奖励，包括独立资金和其他可能构成下一次竞争基础的项目 更新。